ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
Trial Parameters
Brief Summary
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).
Eligibility Criteria
Inclusion Criteria: 1. The subject must be aged between 40 and 70 years. 2. Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography. 3. Patients who have 1 or more CVD risk factors in below; * dyslipidemia or, * diabetes or, * hypertension or, * family history of CVD or, * smoking 4. Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: 1. Individuals who have symptomatic coronary artery disease or heart failure. 2. Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), \>50% carotid stenosis or previous carotid endarterectomy or stent